Abstract：
OBJECTIVE: Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody-drug conjugate (ADC) development, emphasising their transformative potential in cancer care.
RESULTS: ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA\'s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape. ADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.
RESULTS: ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA\'s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape. ADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.
摘要：
目的：我们的综述深入研究了泌尿系恶性肿瘤的进展，并讨论了抗体-药物偶联物（ADC）开发的持续挑战和未来方向。强调他们在癌症治疗中的变革潜力。
结果：ADC已经从血液肿瘤发展到实体瘤，特别是在乳腺癌中，作为单一疗法和联合疗法，现在在转移性泌尿系癌症中至关重要，FDA批准enfortumabvedotin和sacituzumabgovitecan用于转移性尿路上皮癌。转移性前列腺癌的进展，特别是针对PSMA和STEAP1的ADC，值得注意的是，尽管肾细胞癌提出了持续的挑战。在转移性肿瘤中不断寻找药物，复发性睾丸癌景观。ADC已经成为肿瘤学的关键创新，将靶向抗体治疗与强效细胞毒性药物混合，显著推进泌尿系恶性肿瘤的治疗选择。
结果：ADC已经从血液肿瘤发展到实体瘤，特别是在乳腺癌中，作为单一疗法和联合疗法，现在在转移性泌尿系癌症中至关重要，FDA批准enfortumabvedotin和sacituzumabgovitecan用于转移性尿路上皮癌。转移性前列腺癌的进展，特别是针对PSMA和STEAP1的ADC，值得注意的是，尽管肾细胞癌提出了持续的挑战。在转移性肿瘤中不断寻找药物，复发性睾丸癌景观。ADC已经成为肿瘤学的关键创新，将靶向抗体治疗与强效细胞毒性药物混合，显著推进泌尿系恶性肿瘤的治疗选择。
